FDA panel report: January 1998

Circulation

Volumn 97, Issue 23, 1998, Pages 2295-2296

  Thadani, Udho ^a   Roden, Dan M ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; INOTROPIC AGENT; IRBESARTAN; LOSARTAN; TASOSARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLEEDING; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INOTROPISM; LIVER TOXICITY; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0032537612     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.23.2295     Document Type: Note

References (1)

1. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-1428.